MedTrace Logo

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions

NCT00652704 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-26

No results posted yet for this study

Summary

To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent to 100 mg doxycycline (Par) versus Monodox (Oclassen Pharmaceuticals)

Conditions

  • To Determine Bioequivalence Under Fed Conditions

Interventions

DRUG

Doxycycline monohydrate

Capsules, 100 mg, fed

DRUG

Monodox

Capsules, 100 mg, fed

DRUG

Doxycycline Monohydrate

Capsules, 100 mg, fasting

Sponsors & Collaborators

  • Anapharm

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Masson, Pharm.D. · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-07-31
Primary Completion
1999-09-30
Completion
1999-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652704 on ClinicalTrials.gov